Nothing Special   »   [go: up one dir, main page]

WO2009044793A1 - 癌遺伝子を標的とするsiRNA - Google Patents

癌遺伝子を標的とするsiRNA Download PDF

Info

Publication number
WO2009044793A1
WO2009044793A1 PCT/JP2008/067896 JP2008067896W WO2009044793A1 WO 2009044793 A1 WO2009044793 A1 WO 2009044793A1 JP 2008067896 W JP2008067896 W JP 2008067896W WO 2009044793 A1 WO2009044793 A1 WO 2009044793A1
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
expression
targeting
oncogene
inhibiting
Prior art date
Application number
PCT/JP2008/067896
Other languages
English (en)
French (fr)
Inventor
Hidenori Yazawa
Mitsunori Morita
Reiko Sato
Original Assignee
Alphagen Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphagen Co., Ltd. filed Critical Alphagen Co., Ltd.
Publication of WO2009044793A1 publication Critical patent/WO2009044793A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、癌遺伝子の発現を阻害するsiRNAを含む、細胞の増殖を阻害するための組成物を提供する。また癌遺伝子の発現を阻害するsiRNAを用いた癌の治療方法を提供する。 　本発明者らは、まず、PLK-1を標的とする新規設計されたsiRNA（ALG-00345）がその遺伝子発現を著しく阻害すること、アポトーシスを引き起こすことを見出し、さらに静脈内注射によって、ALG-00345がヌードマウス中でUM-UC-3（ヒト膀胱腫瘍）含有異種移植片の増殖を阻止することを、インビボ試験により明らかにした。また、サバイビン特異的DNA/RNAキメラsiRNAを最適化することを試み、サバイビンを標的とするsiRNAベースの抗癌剤は分子標的化薬物として有用であることを見出した。さらに、SKP2およびCKS1に対する最適化RNA/DNAキメラsiRNAが標的遺伝子特異性を示し、そのオフターゲット効果は最小化されることを明らかにし、ヒト血清中で長期の安定性を有することを明らかにした。
PCT/JP2008/067896 2007-10-02 2008-10-02 癌遺伝子を標的とするsiRNA WO2009044793A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96051707P 2007-10-02 2007-10-02
US60/960,517 2007-10-02

Publications (1)

Publication Number Publication Date
WO2009044793A1 true WO2009044793A1 (ja) 2009-04-09

Family

ID=40526217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067896 WO2009044793A1 (ja) 2007-10-02 2008-10-02 癌遺伝子を標的とするsiRNA

Country Status (1)

Country Link
WO (1) WO2009044793A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017319A2 (en) * 2008-08-05 2010-02-11 Mdrna, Inc. Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2010137570A1 (ja) * 2009-05-29 2010-12-02 学校法人慶應義塾 抗ウイルス剤または抗癌剤
JP2012525852A (ja) * 2009-05-08 2012-10-25 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
DE102013003869A1 (de) * 2013-02-27 2014-08-28 Friedrich-Schiller-Universität Jena Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
US9163285B2 (en) 2009-05-06 2015-10-20 Curna, Inc. Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
CN116676392A (zh) * 2023-06-06 2023-09-01 山东大学第二医院 Usp10-mof-anxa2信号通路作为药物靶点在制备治疗食管鳞状细胞癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044188A1 (fr) * 2001-11-21 2003-05-30 Mitsubishi Chemical Corporation Procede pour inhiber l'expression de genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044188A1 (fr) * 2001-11-21 2003-05-30 Mitsubishi Chemical Corporation Procede pour inhiber l'expression de genes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EIJI ASHIHARA ET AL.: "Polo-like kinase-1 o Hyoteki to shita RNA Kansho ni yoru Atarashii Gan Bunshi Hyoteki Chiryoho; also page 169", MOLECULAR TARGET THERAPY OF CANCER, vol. 4, 2006, pages 193 - 201 *
HAJIME FUKANO ET AL.: "Optimization of siRNA for survivin, and its in vitro and in vivo activity against human bladder cancer", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 66, August 2007 (2007-08-01), pages 537, 538 *
HIDENORI YAZAWA ET AL.: "SKP2 and CKS1 as molecular targets for bladder cancer treatment", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 66, August 2007 (2007-08-01), pages 537 *
HIROAKI UCHIDA ET AL. ET AL.: "siRNA Hatsugen Virus Vector o Mochiita Idenshi Chiryo", CLINICAL IMMUNOLOGY, vol. 43, 2005, pages 443 - 450 *
MASATO IKEDA ET AL.: "Hai Gansaibo Kabu ni Okeru ultraviolet C Shosha Ji no survivin Hatsugen Chosetsu Kiko to sono Seibutsugakuteki Yakuwari", MEDICAL JOURNAL OF KINKI UNIVERSITY, vol. 30, 2005, pages 19 - 25 *
MITSUNORI MORITA ET AL.: "Optimization Of RNA/ DNA chimeric siRNA for polo-like kinase-1", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 66, August 2007 (2007-08-01), pages 538 *
YASUSEI KUDO ET AL.: "The effect of Cksl and Skp2 siRNA on the inhibition of cell growth in oral cancer", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 63, 2004, pages 152 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017319A2 (en) * 2008-08-05 2010-02-11 Mdrna, Inc. Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2010017319A3 (en) * 2008-08-05 2010-04-15 Mdrna, Inc. Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
US9163285B2 (en) 2009-05-06 2015-10-20 Curna, Inc. Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
JP2012525852A (ja) * 2009-05-08 2012-10-25 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
WO2010137570A1 (ja) * 2009-05-29 2010-12-02 学校法人慶應義塾 抗ウイルス剤または抗癌剤
DE102013003869A1 (de) * 2013-02-27 2014-08-28 Friedrich-Schiller-Universität Jena Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
WO2014131773A2 (de) 2013-02-27 2014-09-04 Friedrich-Schiller-Universität Jena Verfahren zur gezielten abtötung von zellen durch zur mrna-anbindung ausgerichtete nukleotid-moleküle sowie nukleotid-moleküle und applikationskit für solche verwendung
DE102013003869B4 (de) * 2013-02-27 2016-11-24 Friedrich-Schiller-Universität Jena Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
CN116676392A (zh) * 2023-06-06 2023-09-01 山东大学第二医院 Usp10-mof-anxa2信号通路作为药物靶点在制备治疗食管鳞状细胞癌药物中的应用
CN116676392B (zh) * 2023-06-06 2023-12-05 山东大学第二医院 Usp10-mof-anxa2信号通路作为药物靶点在制备治疗食管鳞状细胞癌药物中的应用

Similar Documents

Publication Publication Date Title
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2009044793A1 (ja) 癌遺伝子を標的とするsiRNA
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009142822A3 (en) 2-f modified rna interference agents
WO2010059702A3 (en) Recurrent gene fusions in prostate cancer
WO2004009769A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
WO2007031091A3 (en) Rna antagonist compounds for the modulation of p21 ras expression
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2012024170A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
WO2012135592A3 (en) Theranostic imaging agents and methods of use
WO2012072096A8 (en) Method for cellular rna expression
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
CN101489383A (zh) 传递方法
Sand et al. MicroRNA in non-melanoma skin cancer
NZ599998A (en) Supercoiled minicircle dna for gene therapy applications
WO2011116152A3 (en) Delivery of agents using interfering nanoparticles
WO2008070477A3 (en) Polymeric short interfering rna conjugates
WO2010085665A3 (en) Targeted delivery system
EP2690175A3 (en) Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
WO2008045576A3 (en) Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
Staedel et al. Inhibition of gastric tumor cell growth using seed-targeting LNA as specific, long-lasting MicroRNA inhibitors
WO2007117121A3 (en) Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834898

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A OF 16-07-2010)

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08834898

Country of ref document: EP

Kind code of ref document: A1